- Home
- CHH vs CORT Comparison
CHH vs CORT Comparison
Compare CHH & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHH | CORT |
|---|---|---|
| Founded | 1939 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.7B |
| IPO Year | 1997 | 2001 |
Fundamental Metrics
Financial Performance| Metric | CHH | CORT |
|---|---|---|
| Price | $100.27 | $33.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $112.92 | $105.20 |
| AVG Volume (30 Days) | 522.9K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | ★ 27.42 | N/A |
| EPS | ★ 7.90 | 0.82 |
| Revenue | ★ $1,596,793,000.00 | $761,407,000.00 |
| Revenue This Year | $66.74 | $26.08 |
| Revenue Next Year | $0.49 | $31.04 |
| P/E Ratio | ★ $12.42 | $42.33 |
| Revenue Growth | 0.75 | ★ 12.79 |
| 52 Week Low | $84.04 | $28.66 |
| 52 Week High | $136.45 | $117.33 |
Technical Indicators
Market Signals| Indicator | CHH | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 40.77 |
| Support Level | $99.40 | $32.40 |
| Resistance Level | $100.40 | $41.92 |
| Average True Range (ATR) | 3.23 | 1.26 |
| MACD | -0.02 | 0.48 |
| Stochastic Oscillator | 49.38 | 43.61 |
Price Performance
Historical ComparisonAbout CHH Choice Hotels International Inc.
At year-end 2025, Choice Hotels operated 657,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (27% of the company's total rooms), while Ascend and Cambria (10%) are lifestyle and select-service brands, and WoodSpring (5%) is the company's largest extended-stay brand. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2024.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.